Author

M. Magnen

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Physiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Organism:mouse· 1 Assay:scRNA-seq· 1

Frequent Co-Authors

M. R. Looney· 3 shared A. A. Rao· 2 shared C. M. Hendrickson· 2 shared D. J. Erle· 2 shared K. H. Hu· 2 shared L. Rodriguez· 2 shared M. F. Krummel· 2 shared P. G. Woodruff· 2 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

M. R. Looney

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Optimizing anesthesia and delivery approaches for dosing into lungs of mice

Y. Seo, L. Qiu, M. Magnen, C. Conrad, S. F. Moussavi-Harami, M. R. Looney, S. J. Cleary

This study compares pulmonary dosing efficiency in mice under different anesthetic and delivery methods, finding that ketamine/xylazine anesthesia and oropharyngeal aspiration improve lung delivery compared to isoflurane and intranasal dosing.

bioRxiv · Feb 1, 2023Physiology

Immediate myeloid depot for SARS-CoV-2 in the human lung

M. Magnen, R. You, A. A. Rao, R. T. Davis, L. Rodriguez, C. R. Simoneau, L. Hysenaj, K. H. Hu, The UCSF COMET Consortium, C. Love, P. G. Woodruff, D. J. Erle, C. M. Hendrickson, C. S. Calfee, M. A. Matthay, , M. R. Looney

The paper investigates early SARS-CoV-2 infection in human lung myeloid cells, finding rapid viral tropism, ACE2 dependence, and poor interferon induction, suggesting a myeloid depot for viral persistence.

bioRxiv · Apr 28, 2022Immunology

Global Absence and Targeting of Protective Immune States in Severe COVID-19.

A. J. Combes, T. Courau, N. F. Kuhn, K. H. Hu, A. Ray, W. S. Chen, S. J. Clearly, N. W. Chew, D. Kushnoor, G. C. Reeder, A. Shen, J. Tsui, K. J. Hiam-Galvez, P. Munoz-Sandoval, W. S. Zhu, , M. F. Krummel

The paper identifies that severe COVID-19 patients lack ISG-expressing cells and have antibodies that block their production, contrasting with mild cases.

bioRxiv · Oct 28, 2020Immunology